Patents Examined by Lynn Y Fan
  • Patent number: 12161653
    Abstract: This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: December 10, 2024
    Assignee: Allergan Sales, LLC
    Inventor: Patricia Walker
  • Patent number: 12115198
    Abstract: The invention relates to direct-fed microbials for use in improving reproductive performance in animals, decreasing death loss and/or off-feed events in animals, improving milk production and/or milk quality in dairy animals, and inhibiting a disease or disorder in dairy animals selected from the group consisting of milk fever, ketosis, retained placenta, metritis, pneumonia, and displaced abomasum. More particularly, the invention relates to isolated Bacillus strains 86, 300, 101, 235, 177, and 102, and strains having all of the identifying characteristics of these strains, for uses comprising the above-mentioned uses.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: October 15, 2024
    Assignees: ·MICROBIAL DISCOVERY GROUP, LLC, UNITED ANIMAL HEALTH, INC.
    Inventors: Michael R. King, Sona Son, Elizabeth Galbraith, Samanta R. Fensterseifer, Ricardo P. Arias
  • Patent number: 12082575
    Abstract: A perfusion stock composition, for preserving a donor organ for transplantation, comprising: a source of 60 to 100 mM Na+; a source of 10 to 20 mM K+; a source of 5 to 10 mM Mg2+; a source of 0.25 to 0.75 mM Ca2+; 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (IviES), N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), or N/-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); a source of 10 to 30 mM HCO3; 1 to 30 mM glucose; 1 to 20 U/L insulin; 1 to 10 mM fructose diphosphate or a salt thereof; 1 to 40 mM aspartate or glutamate; 1 to 10 mM adenosine, cAMP or cGMP; 1 to 10 mM reduced glutathione; and 30 to 100 mM lactobionate or mannitol; and, optionally, a diluent. The present disclosure also provides a perfusion composition, a kit, a method, and a perfusion apparatus, each related to the perfusion stock composition.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: September 10, 2024
    Assignee: Organ Transport Pty Ltd
    Inventors: Franklin Rosenfeldt, Marlin Alford, Robert Dowben
  • Patent number: 12070530
    Abstract: Provided is a method of preparing an ECM material and the product of the method. The method comprises processing the ECM material with a reactive oxygen species or a reactive nitrogen species. Also provided are methods of use of the product.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: August 27, 2024
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Samuel LoPresti, Bryan N. Brown
  • Patent number: 12061143
    Abstract: The invention is directed to a method for rapidly determining antibiotic susceptibility in bodily fluid samples based on rigorous multidimensional statistical metrics. In some embodiments, the method incorporates flow cytometry to determine susceptibility. In preferred embodiments, the method is adapted for use with samples with low bacterial counts.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: August 13, 2024
    Assignee: Georgia Tech Research Corporation
    Inventors: Robert Martin Dickson, Tzu-Hsueh Huang
  • Patent number: 12060574
    Abstract: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 13, 2024
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventor: Eduardo N. Mitrani
  • Patent number: 12042518
    Abstract: The subject invention provides compositions for promoting good health. Specifically, the subject composition can be used for alleviating symptoms of indigestion, abdominal pain, and cephalic syndrome, including in healthy subjects. In preferred embodiments, the compositions comprise an effective amount of one or more Lactobacillus isolates. Preferably, the bacteria used as an active ingredient in the compositions of the subject invention are of the L. johnsonii N6.2 strain. The subject invention also provides methods for alleviating symptoms of indigestion, abdominal pain, and cephalic syndrome. These methods comprise the administration of a composition of the subject invention, wherein the composition preferably comprises an effective amount of one or more Lactobacillus isolates. Even more preferably, the subject method utilizes an effective amount of L. johnsonii N6.2.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: July 23, 2024
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Graciela Liliana Lorca, Claudio Gonzalez
  • Patent number: 12029834
    Abstract: Provided herein are meniscus implant compositions, as well as method for making and using the same. The subject meniscus implants find use in repairing and/or replacing damaged or diseased meniscal tissue in a mammalian subject.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 9, 2024
    Inventors: Sam Wadsworth, Simon Beyer, Tamer Mohamed, Konrad Walus, Mohammad Mostofa Kamal Khan, Elli Kapyla, Julia Hwang, Joe Ault
  • Patent number: 12023416
    Abstract: Methods of manufacturing collagen fibers comprising any one, a combination or all of the following: at least partially decellularizing a collagenous tissue; homogenizing the collagenous tissue; separating at least a portion of collagen fibers from the collagenous tissue; exposing the collagen fibers to an acidic solution before or after the separating; and forming at least one of a suture, a woven structure, a knitted structure, or a bioprosthetic device with the collagen fibers.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: July 2, 2024
    Assignee: EDWARDS LIFESCIENCES CORPORATION
    Inventor: Tara J. Tod
  • Patent number: 12011463
    Abstract: A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: June 18, 2024
    Assignee: Reapplix ApS
    Inventors: Rasmus Lundquist, Niels Erik Holm
  • Patent number: 12005098
    Abstract: The present invention relates to compositions comprising: malt extract including a plurality of enzymatically active enzymes including at least fructanase and amylase; one or more medium-chain triglycerides (MCTs) and/or at least one biologically acceptable metal component and use of those compositions as veterinary and human medicaments.
    Type: Grant
    Filed: November 23, 2017
    Date of Patent: June 11, 2024
    Assignee: PEPSIS LIMITED
    Inventors: John Hunter, Rosemary Waring
  • Patent number: 12006524
    Abstract: An object of the present invention is to provide a method for eliminating the hydroxyl group at the 9-position of a urolithin to produce another kind of urolithin. This object is achieved by a method for producing a second urolithin, including Step (a): allowing, in a solution containing a first urolithin, a microorganism having an ability to produce the second urolithin from the first urolithin to produce the second urolithin from the first urolithin.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: June 11, 2024
    Assignee: DAICEL CORPORATION
    Inventors: Masatake Kudoh, Takanori Nakajima, Hiroaki Yamamoto
  • Patent number: 11970518
    Abstract: The present disclosure is generally directed to an anucleated cell-based platforms for encapsulation and delivery of agricultural compounds. Disclosed herein are compositions for the stable and targeted delivery of agricultural compounds within achromosomal and/or anucleated cells. The present disclosure also provides methods of improving encapsulation and retention of agricultural compounds in achromosomal and/or anucleated cells.
    Type: Grant
    Filed: March 28, 2023
    Date of Patent: April 30, 2024
    Assignee: AgroSpheres, Inc.
    Inventors: Ameer Hamza Shakeel, Sepehr Zomorodi, Joseph Thomas Frank, Zachery George Davis, Payam Pourtaheri
  • Patent number: 11944668
    Abstract: The invention concerns the improvement of metabolic and digestive health of humans by providing diagnostic methods for enterometabolic disorders such as IBS and IBD and/or the treatment of IBS and IBD by compositions comprising enzyme rich malt extract (ERME).
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: April 2, 2024
    Assignee: PEPSIS LIMITED
    Inventors: John Hunter, Rosemary Waring
  • Patent number: 11930809
    Abstract: Described herein are enhanced compositions and methods for storing biomaterials. In certain aspects, these biomaterials include natural and engineered eukaryotic tissues. The methods described herein include storing these biomaterials in such a manner that reduces or prevents the loss of biomaterial properties (e.g., extracellular matrix integrity, cell viability, or a combination thereof) occurring either during storage or after removal of the biomaterial from storage. In certain aspects, these biomaterials will be stored in animal product-free solutions containing an agent that prevents or reduces the loss of extracellular matrix integrity.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: March 19, 2024
    Assignee: LIFELINE SCIENTIFIC, INC.
    Inventor: Kelvin G. M. Brockbank
  • Patent number: 11919941
    Abstract: Soluble, self-assembling collagens derived from tissues are extensively characterized such that one can predict and customize the final collagen-fibril matrix with respect to fibril microstructure (i.e., fibril density, interfibril branching), viscoelasticity and proteolytic degradability. As shown herein these matrices template and direct the deposition of mesoporous silica at the level of individual collagen fibrils. The fibril density, silicic acid concentration, and time of exposure to silicifying solution were varied and the resulting hybrid materials were analyzed by scanning electron microscopy, energy-dispersive x-ray spectroscopy, and rheology. Microstructural properties of the collagen-fibril template are preserved in the silica surface of hybrid materials.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: March 5, 2024
    Assignee: Purdue Research Foundation
    Inventors: Jenna Leigh Rickus, Sherry L. Voytik-Harbin, Jennifer L. K. Rich
  • Patent number: 11920173
    Abstract: Disclosed are non-naturally-occurring microorganisms for the production of N-acetylneuraminic acid, a method for the production of N-acetylneuraminic acid by fermentation of the non-naturally-occurring microorganisms, and nutritional compositions containing N-acetylneuraminic acid which has been produced by fermentation of the non-naturally-occurring microorganisms.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 5, 2024
    Assignee: Chr Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg
  • Patent number: 11911448
    Abstract: The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention further provides hemostatic compositions comprised of liquid thrombin, glycerol and gelatin. Further provided herein is a method for the large-scale production of a sterile liquid thrombin composition comprised of glycerol.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: February 27, 2024
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez Ilan, Omri Faingold, Sivan Doron
  • Patent number: 11878050
    Abstract: The present invention includes methods for reducing biofilm present on a surface comprising contacting the surface with a composition under conditions wherein the presence of the biofilm on the surface is reduced and antibiotic activity is increased, wherein the composition comprises at least two glycoside hydrolases and an antibiotic.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: January 23, 2024
    Assignee: Texas Tech University System
    Inventors: Kendra Rumbaugh, Derek Fleming
  • Patent number: 11865143
    Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: January 9, 2024
    Assignee: AKER BIOMARINE ANTARCTIC AS
    Inventors: Inge Bruheim, Snorre Tilseth, Daniele Mancinelli